REGULATORY REQUIREMENTS FOR CLINICAL-EVALUATION OF ANTIMICROBIAL AGENTS

被引:2
|
作者
CHRIST, W
机构
[1] Institute for Drugs, Federal Health Office, Berlin 65, 1000
关键词
D O I
10.1007/BF01964299
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Evaluation of antimicrobial agents in governed mainly by interaction between the pharmaceutical industry and regulatory authorities. The 1977 FDA guidelines have been setting the standards for more than a decade now. Basic principles of the 1977 guidelines remain valid, however changes in the definition of end-points of response, as measured by both clinical and microbiological criteria, have occurred. The new (draft) FDA guidelines and the 1989 guidelines of the British Society of Antimicrobial Chemotherapy are more consistent with contemporary concepts of treatment. In general, the differences in the requirements are minimal with a few exceptions, namely the requirements concerning blinding and assessment of clinical efficacy by site of infection and by organism in the FDA guidelines. © 1990 Friedr. Vieweg & Sohn Verlagsgesellschaft mbH.
引用
收藏
页码:537 / 541
页数:5
相关论文
共 50 条